Background. The Cholesterol Lowering Atherosclerosis Study has demonstrated beneficial effect of colestipol/niacin on coronary atherosclerosis using a panel-determined global coronary change score. We now report treatment group comparisons using quantitative coronary angiographic (QCA) measures from all processable segments in 85 of 162 randomly selected baseline/2-year film pairs.
Background. The Cholesterol Lowering Atherosclerosis Study has demonstrated beneficial effect of colestipol/niacin on coronary atherosclerosis using a panel-determined global coronary change score. We now report treatment group comparisons using quantitative coronary angiographic (QCA) measures from all processable segments in 85 of 162 randomly selected baseline/2-year film pairs.
Methods and Results. Treatment benefit was established for percent stenosis for either continuous or categorical analyses with regression established regardless of the per-patient scoring procedure. In addition, treatment benefit favoring regression was established in some cases for roughness and for percent involvement, a longitudinal estimate of the percent of coronary surface involved by raised lesions. Benefit on minimum diameter was directly related to whether the segment was proximal to a graft insertion and hemodynamically related to the bypass graft. QCA correlates of panel-determined progression were increases in percent stenosis and numbers of occluded lesions in native arteries and the number of progressing lesions in bypass grafts.
Conclusions. These results demonstrate that a variety of computer measures can be used as end points in coronary angiographic therapy trials, but change in percent stenosis correlates best with visual panel assessments and best reflects the treatment benefit; when treatment effect sizes are moderate to large, the required sample size of coronary angiographic trials can be reduced when QCA is used. (Circulation 1992;86:1701-1709) KEY WoRDs * atherosclerosis * clinical trials * quantitative coronary angiography * regression C ontrolled clinical trials testing risk factor reduction with angiographic end points provide a central mechanistic link in the evidence that coronary atherosclerosis is reversible. Observations in human angiograms bridge a gap between therapy trials demonstrating reduced coronary heart disease mortality and morbidity rates1 and treatment effects in animal models.2'3 Five angiographic trials (FATS, POSCH, UCSF SCOR, the Lifestyle Heart Trial, and STARS)4-8 have recently confirmed and extended the 1987 findings of coronary regression reported by the Cholesterol Lowering Atherosclerosis Study (CLAS)9 using related but essentially different film evaluation methods: human panel readerss and computerized image processing (referred to as quantitative coronary angiography, QCA), which includes both automated edge detection78 and hybrid human-computer methods. 4, 6 Percent stenosis has been used in all studies to establish baseline severity of individual lesions and on-trial improvement or deterioration.4-13 Estimated effects on coronary flow characteristics or change in lesion shape and/or length have been secondary lesionspecific end points in two studies.4 '7 Other factors used in data analysis have been severity of lesions at baseline4'8'10 and hemodynamic effects of lesion position in the coronary tree.4 9 Diverse procedures have been used to combine per-lesion data from each patient into a per-patient score for comparison of test and control groups. Unresolved questions that can significantly influence combining per-lesion scores into per-patient scores relate to 1) whether lesions should be considered individually or grouped by vessel segment and 2) whether lesions change independently. Current Three sequential frames exposed during end diastole were digitized unless unobstructed, matched end-diastolic frames could not be found; in that case, three sequential frames from other phases of the cardiac cycle were used.'718 For each film, all processable segments (defined from branch to branch) were tracked and evaluated. In the case of a stenosis residing at a branch point, the automated edge tracking algorithm handles this lesion as two different segmental lesions.
To find the edges of a vessel, the computer operator first identified the approximate vessel midline with a cursor. The computer algorithm then searched perpendicular to this midline to find points of maximum intensity gradient that were identified as vessel "edges."
After the edges were located, a new midline was defined as the smoothed midpoints of the edges, and the tracking process was repeated. This two-pass tracking was used to minimize the effect of the selection of the original midline by the technician. The search was restricted to a window of pixel values centered on the previously detected edge point.
Portions of a segment with localized ectasia were manually eliminated by the computer operator, and the normal diameter was computed from the nonectatic portion of the segment. If a segment showed diffuse ectasia, the normal diameter was defined as "missing,"
and any measure requiring a normal diameter (e.g., percent stenosis) was not computed.
Because absolute measures of lumen geometry (for example, average and minimum diameter) were made in addition to percent stenosis and roughness, edge coordinates were corrected for pincushion distortion measured from the image of a 1-cm anteroposterior grid filmed at the beginning of each angiogram. All segmental measures were averaged over the three sequential digitized frames; diameters were converted to millimeters by a scaling factor using the known diameter of the catheter and corrections from the radiographic grid. The coefficient of variation of average and minimum diameter of the segment for the three frames was calculated and used to monitor image and edge tracking quality. When the coefficient of variation of the average diameter exceeded 5% or that of the minimum diameter exceeded 13%, the operator reviewed the edge tracking of the frames in question and corrected detectable errors (e.g., overlooked crossing vessel shadows). If the edge tracking problems were not correctable (e.g., if the segment was not uniformly opacified, the segment was too small, or the image quality was poor), the operator eliminated the segment from the data base. Lumen geometry measurements for acceptable sequential frames were then averaged.
QCA Data Base
Eighty-five (of 162) pairs of panel-read angiograms were randomly selected for analysis by QCA. The average (±+SD) global coronary change score for this set of angiograms was 0.5±1.0 compared with 0.6+±0.8 for the set of angiograms not analyzed in this study (NS) . Similarly, no significant differences in average global coronary change scores were found between these sets of angiograms within each treatment group.
In total, 731 native arterial segments were tracked and evaluated by QCA with a median of 326 measurable diameters per segment and a median length of 25 mm. In addition, 352 bypass graft segments were tracked and evaluated by QCA with a median of 517 measurable diameters per segment and a median length of 39 mm. The QCA-evaluable segments represented 50% of those identified by the panel; the majority of nonevaluable segments were those with large stenoses (.80%).18 Each segment was characterized by 1) segment type (native artery or bypass graft), 2) native artery vessel location (left main, left anterior descending, circumflex, diagonal, marginal, right coronary, right coronary posterior descending, or other unnamed vessels), and 3) graft status of the native artery (proximal to a graft insertion and hemodynamically related, proximal to a graft insertion and hemodynamically unrelated, distal to a graft insertion and hemodynamically related, some combination of the previous, or ungrafted).
A native coronary artery segment was classified as proximal to a graft insertion and hemodynamically related if it transmitted blood that mixed with blood traversing the graft. A native artery segment was classified as proximal to a graft insertion and hemodynamically unrelated if it did not transmit blood that mixed with blood traversing the graft. A native coronary artery segment was classified as distal to a graft insertion and hemodynamically related if some of the blood passing through the segment was transmitted by the graft.
The QCA data base consisted of 13 measures for matched segments at baseline and at 2 years after therapy. We report on four QCA measures that are representative of all 13 measures: 1) the minimum lumen diameter (millimeters) defined as the third percentile of the distribution of diameters within the segment, 2) percent diameter stenosis within the segment (of the most severe narrowing if more than one lesion was present) defined as 100 (1-minimum diameter/ normal diameter); the "normal" diameter was taken to be the 90th percentile of the distribution of diameters within the segment, 3) roughness (millimeters) defined to be the root mean square of the difference between the measured diameter and a fitted lumen diameter obtained by fitting a least-squares line to the diameters, and 4) percent involvement defined as the ratio of the length of the segment with diameters less than 80% of all diameters in the segment to the total length of the segment.
The third and 90th percentile of segment diameters were chosen to represent the minimum and normal lumen diameters, respectively, in order to minimize the effects of image noise of the edge tracking process (i.e., to eliminate the possibility that poorly measured edge points might produce a large error in stenosis measurement). The 90th percentile estimate for the normal diameter was previously used in processing femoral angiograms.14 The third percentile was selected for the minimum diameter estimate because of the proportionally smaller number of edges that typically contribute to the most narrow portion of the vessel. Small lesions might remain undetected if a larger percentile value was used.
Statistical Analyses
Both continuous and categorical methods of analysis were used to arrive at per-patient estimates of the effect of treatment. The significance level was set at 0.05; tests of hypotheses were two sided.
End Points Analyzed as Continuous Variables
Continuous analyses were performed separately for segments in the native arteries and for segments in the bypass grafts in order to arrive at per-patient estimates of the effect of treatment. The average change (2-year minus baseline) in each QCA measure was tested against zero within each treatment group and tested for equality between treatment groups, both tests using a method by Rosner.19 In this method, the unit of analysis is the segment. The test procedure adjusts for the intraclass correlation among the segments within any given patient to permit testing for means on a perpatient basis. In addition, we included as a covariate the baseline value of the QCA measure for each segment because baseline levels were found to be a significant correlate of QCA-measured change.
End Points Analyzed as Categorical Variables
For the categorical analysis, we used an adaptation of the National Heart, Lung, and Blood Institute scoring procedure to first classify segments and then to classify patients on the basis of measured changes in both the native artery and bypass graft segments. 13 For each QCA measure, we classified segments as progressing, regressing, or not changing on the basis of the size of the change in that measure. For percent stenosis, we classified a segment as regressing when the decrease was greater than +10% and as progressing when the increase was greater than + 10%; when the change was in the range -10% to + 10%, we classified the segment as unchanged. The choice of a 10% difference was regarded as visually convincing of change in a side-by-side comparison of arteriograms by Brown and 
Treatment Effect Sizes by Segment Characteristics
A multivariate analysis was carried out for each QCA measure in order to identify segment characteristics (e.g., segment type, vessel location of segment, and graft status of segment) associated with the 2-year outcome regardless of treatment assignment. These analyses also used the approach by Rosner'9 and also included baseline values of each QCA measure as covariates.
For each significant segment characteristic, we then calculated the treatment effect size. The effect size contrasted on a per-patient basis the mean change in a QCA measure (for example, percent stenosis) for drugtreated patients with that for placebo-treated patients relative to the variance of the change in the QCA measure. Mean changes were computed for segments with the significant characteristic (for example, segments proximal to the graft insertion and hemodynamically related), whereas variance was computed for all native arterial segments. In symbols, then, the effect size is defined as The intraclass correlation coefficient for each QCA measure was small, indicating that the segments respond independently of each other. In the native arteries, these correlations were percent diameter stenosis (0.04), total roughness (0.02), third percentile diameter (0.08), and percent involvement (0.05). In the bypass grafts, correlations were percent diameter stenosis (-0.02), total roughness (0.04), third percentile diameter (0.19), and percent involvement (0.03). Relation of QCA to Panel-Based Global Coronary Score Table 3 summarizes the results of the regression analyses relating QCA measures with the panel-based global coronary change score. The sign of the correlation coefficient indicates the direction of the association. In the native arteries, the significant univariate correlates with panel-based progression were 1) increased percent stenosis (p<0.001), 2) decreased minimum diameter (p=0.009), 3) increased numbers of progressing segments (p=0.004), and 4) increased numbers of occluded segments (p=0.008). In the bypass grafts, the significant univariate correlates were 1) increased percent stenosis (p=0.02), 2) increased progressing segments (p=0.0002), and 3) increased numbers of occluded segments (p=0.03).
End Points Analyzed as Categorical Variables
When evaluated multivariately using stepwise multiple regression methods, the three independent and significant correlates of panel-based coronary change score were 1) increased percent stenosis in the native Graph illustrates treatment effect size for minimum diameter (mm), percent diameter stenosis, roughness (mm), and percent involvement. Treatment effect sizes are calculated for 1) all native arterial segments (NA), 2) native arterial segments proximal to a graft insertion and hemodynamically related (NAPHR), 3) native arterial segments distal to a graft insertion and hemodynamically related (NADHR), and 4) bypass grafts (BG) . See text for definitions ofsegments hemodynamically related to graft insertion. The effect size, which measures the benefit of drug therapy relative to that of the placebo, is calculated as IXD -XPI/V(xD) + V(xp)]'12 where XD and x are the mean changesfor the drug andplacebo in the segments with a given characteristic and [V(xD) +V(xp)]j2 is the pooled standard deviation of the changes computed for all segments in the native arteries. The pooled standard deviations are 0.15 mm, minimum diameter; 11.3%, percent stenosis; 0.52 mm, roughness; and 13%, percent involvement. In contrast to these findings, an analysis of the in CLAS (performed for safety monitoring by an unblinded external advisory committee) did not reveal a significant therapy effect. The highly significant effect we report from a 52% random sample of CLAS patients using QCA measures may be attributed at least in part to greater precision in image processing. On the other hand, because image processing was applied to a 49% subset of lesions that were, on average, less severe than the larger population visible to panelists,18 these segment-based results may be influenced by lesion-selection bias leading to increased treatment response.
Percent Stenosis as an End Point Measure
The use of percent stenosis, the classical coronary lesion severity measure, is strongly supported in our data. Percent stenosis is widely used in current clinical trials for establishing disease improvement or deterioration regardless of film evaluation procedure.4-13 '16 Comparison of treatment effect sizes (Figure 1 ) indicates that percent stenosis is the single best measure for discriminating drug treatment from placebo in all native arterial segments (effect size, 30%). However, when the analysis was restricted to low or alternating flow areas, (i.e., hemodynamically related segments proximal to a graft insertion), the effect size increased to 53%, comparable to that reported in FATS4 for the lovestatin/ colestipol-treated patients (effect size for nine proximal segments in ungrafted arteries, 61%; for all segments, 53%) but less than that reported for colestipol/niacintreated patients (effect size for nine proximal segments in ungrafted arteries, 85%; for all segments, 84%).
Roughness as an Alternative End Point
Although the presence or absence of unstable angina and myocardial infarction have been shown to be associated with angiographic measures of native coronary artery vessel edge roughness,2021 QCA estimates of coronary vessel edge roughness have not been reported in controlled clinical trials. In pilot studies of computerized image processing of femoral arteries, we found femoral artery edge roughness to be significantly correlated with atherosclerosis and cholesterol content of the vessel wall.22 In addition, we have reported that femoral artery edge roughness measurements demonstrated significant beneficial effects from colestipol/niacin therapy in CLAS patients.23 In this study, roughness in coronary native artery segments was significantly reduced in colestipol/niacin-treated patients (Table 1) , with no significant change in placebo patients or significant between-group differences. Furthermore, when roughness was analyzed categorically, significant regression was found for drug-treated patients compared with placebo-treated patients for the rules based on classifying two or more segments (Rules 2 and 4, Human panel readers can provide both percent stenosis lesion severity estimates and global change score, an overall assessment of change in varied pathology of the native coronary arteries and bypass grafts. Global change score has the advantage of reflecting the accumulated clinical wisdom of experienced angiographers but suffers the disadvantage of lacking precise description. To determine which QCA descriptors were independently associated with coronary outcome, we chose the panelbased global coronary change score as a coronary outcome measure external to the QCA process.
Change in percent stenosis was the fundamental lesion severity measure used by human film panelists to determine the global coronary changes scores in CLAS films. QCA measures of percent stenosis, analyzed both nificant treatment effects reported by panelists. Long and coworkers36 have developed an expert system predicting human panel-derived global change scores using the sum of visual estimates of change in percent stenosis. We have extended these findings and have determined that computer-derived measures are significantly correlated with the global coronary change score. In CLAS films, significant QCA correlates of panel-based progression in both the native arteries and bypass grafts were increased percent stenosis, increased numbers of progressing segments, and increased numbers of occluded segments. In addition, decreased minimum diameter in the native arteries was found to be a significant correlate of panel-based progression. When evaluated multivariately, panel-based progression was found to be correlated with increased percent stenosis in the native arteries, increased number of occluded lesions in the native arteries, and increased number of progressing lesions in the bypass grafts.
Thirty-six percent of the variability in the global coronary change score was explained by the QCA measures. It is possible that a larger percentage of the variability could have been explained if more lesions >80% could have been measured by QCA. Lack of an appropriate segment of uninvolved vessel and the difficulty of the maximum gradient algorithm in tracking vessels more than 80% occluded were the most common reasons why our automated method of QCA could not be applied to advanced lesions. 18 Computer procedures that measure percent stenosis require uninvolved reference segments (used to determine normal vessel contours) immediately distal or proximal to a target lesion. When nearby vessel segments are not usable, human readers estimated vessel contours from a distant vessel segment or from other views of the same segment.
Study Limitations
In CLAS, as in other human coronary angiographic trials, it is not technically or ethically possible to establish the validity of the angiographic change measures by comparison with "true" anatomy or histopathology. We have adopted the criterion of discrimination between colestipol/niacin-treated and placebo-treated subjects for evaluating QCA measures as indicators of atherosclerosis change. Our rationale is that monotherapy with the bile acid binding resin cholestryamine (activity similar to colestipol) and monotherapy with niacin have each been shown to reduce ischemic heart disease mortality rates.37,38 Furthermore, colestipol plus niacin treatment has been shown to beneficially reduce cardiac event rates4 and has been shown to influence coronary anatomy in three independent studies.4 '6,9 An additional approach to the evaluation of individual QCA measures is suggested by the recent finding that human panel-derived global coronary change scores from baseline to 3 years were significantly predictive of ischemic heart disease events over 7 years of follow-up in POSCH. 5 These results indicate that selection of a gold standard for computerized coronary angiographic measures used in clinical trials could be based on an ability to predict coronary event rates. The predictive ability of combined human scores and comas continuous and categorical variables, confirmed sigputer-derived measures could also be evaluated.
Conclusions
These results demonstrate that 1) a variety of computer measures can be used as end points in coronary angiographic therapy trials, but change in QCA-measured percent stenosis correlates best with visual panel assessments and best reflects the treatment benefit and 2) when treatment effect sizes are moderate to large, the required sample size of coronary angiographic trials can be reduced when QCA is used.
